A Randomized, Open Label, Clinical Trial of the Pharmacokinetics of Azithromycin Following a Single Dose of Azithromycin Sustained Release (2 Gram) or Commercial Azithromycin Tablet (500 mg) to Cancer Patients That Require Lung Surgery

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2004

Study Completion Date

April 30, 2005

Conditions

Pharmacokinetics

Interventions

DRUG

azithromycin immediate release (Zithromax)

azithromycin IR 500 mg tablet by mouth for 1 dose

OTHER

placebo

DRUG

azithromycin SR

2.0 g by mouth in the form of liquid for 1 dose

OTHER

placebo

Trial Locations (1)

Pfizer Investigational Site, Pisa